Maze Therapeutics counsel sells 3,993 shares

Maze Therapeutics’ General Counsel reported sales of 3,993 shares mainly to cover tax withholding on vested RSUs.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) reported that its General Counsel and Corporate Secretary, Courtney Phillips, sold a total of 3,993 shares of common stock on September 2–3, 2026. The company states these sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 3,993 shares

Net Sell 4 txns

Insider Courtney Phillips

Role GC and Corp. Secretary

Sold 3,993 shs ($105K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F4	1,990	$26.0133	$52K
Sale	Common Stock F1	22	$25.78	$567.16
Sale	Common Stock F1, F2	1,738	$26.376	$46K
Sale	Common Stock F1, F3	243	$27.1211	$7K

Holdings After Transaction: Common Stock — 7,007 shares (Direct)

Footnotes (4)

1. F1. The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive.

Key Figures

Total shares sold: 3,993 shares Shares sold September 2, 2026: 1,981 shares Shares sold September 3, 2026: 2,012 shares +5 more

8 metrics

Total shares sold 3,993 shares Aggregate common stock sales by Courtney Phillips on September 2–3, 2026

Shares sold September 2, 2026 1,981 shares Two common stock sale transactions on September 2, 2026

Shares sold September 3, 2026 2,012 shares Two common stock sale transactions on September 3, 2026

Sale price example (Sept 2 weighted avg) $26.3760 per share Weighted average price for 1,738-share sale on September 2, 2026

Sale price example (Sept 2 weighted avg) $27.1211 per share Weighted average price for 243-share sale on September 2, 2026

Sale price example (Sept 3 weighted avg) $26.0133 per share Weighted average price for 1,990-share sale on September 3, 2026

Sale price example (Sept 3 single price) $25.7800 per share Price for 22-share sale on September 3, 2026

Overall price range $25.743–$27.40 per share Full range of prices for the multiple transactions, as disclosed in footnotes

Key Terms

restricted stock units, tax withholding obligations, weighted average price

3 terms

restricted stock units financial

"incurred in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares ... sold to satisfy tax withholding obligations incurred"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

What insider transaction did MAZE report for Courtney Phillips?

Maze Therapeutics reported that General Counsel and Corporate Secretary Courtney Phillips sold a total of 3,993 shares of common stock on September 2–3, 2026, in transactions the company describes as sales to satisfy tax withholding obligations from vested restricted stock units.

How many MAZE shares were sold and on which dates?

A total of 3,993 shares of Maze Therapeutics common stock were sold by Courtney Phillips: 1,981 shares on September 2, 2026 and 2,012 shares on September 3, 2026, across four reported open-market or private sale transactions.

What prices were the MAZE shares sold for in this Form 4?

Reported sale prices ranged from $25.743 to $27.40 per share. Individual transactions used weighted average prices of $26.3760 and $27.1211 on September 2, 2026, and $26.0133 and $25.7800 on September 3, 2026, as disclosed in the footnotes.

Why did Courtney Phillips sell MAZE shares according to the filing?

The filing states that the reported transactions represent shares of Maze Therapeutics common stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units, indicating the sales were linked to equity compensation vesting.

Were the MAZE insider sales made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for these transactions, and the document-level checkbox for such a plan is not marked as being in effect for the reported sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:27 PM Accepted by SEC EDGAR 09/04/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Courtney Phillips

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GC and Corp. Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		1,738	D	$26.376(2)	9,262	D
Common Stock	09/02/2026		S(1)		243	D	$27.1211(3)	9,019	D
Common Stock	09/03/2026		S(1)		1,990	D	$26.0133(4)	7,029	D
Common Stock	09/03/2026		S(1)		22	D	$25.78	7,007	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive.

	/s/ Courtney Phillips	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)